ArticleInternational urology and nephrology2017
MicroRNA-155-induced T lymphocyte subgroup drifting in IgA nephropathy.
Article in International urology and nephrology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- MicroRNAs diagnostic value or IgAN: a meta-analysis.BMC nephrology · 2025Pooled it
- Identification of susceptibility loci and relevant cell type for IgA nephropathy in Han Chinese by integrative genome-wide analysis.Frontiers of medicine · 2024Pooled it
- Intrinsic renal cells induce lymphocytosis of Th22 cells from IgA nephropathy patients through B7-CTLA-4 and CCL-CCR pathways.Molecular and cellular biochemistry · 2018Trial
- Causal relationships between immune cell phenotypes and primary glomerular diseases: genetic evidence from bidirectional Mendelian randomization study.Clinical kidney journal · 2025Article
- Sequential administration of paricalcitol followed by IL-17 blockade for progressive refractory IgA nephropathy patients.Scientific reports · 2024Article
- Review
- An Update on the Genetics of IgA Nephropathy.Journal of clinical medicine · 2023Review
- Immune abnormalities in IgA nephropathy.Clinical kidney journal · 2023Review
- Omics are Getting Us Closer to Understanding IgA Nephropathy.Archivum immunologiae et therapiae experimentalis · 2023Review
- Noncoding RNAs associated with IgA nephropathy.Journal of nephrology · 2023Review
- Review
- The influences of α-hemolytic Streptococcus on class switching and complement activation of human tonsillar cells in IgA nephropathy.Immunologic research · 2022Article
- Title IgA Nephropathy and Oral Bacterial Species Related to Dental Caries and Periodontitis.International journal of molecular sciences · 2022Review
- MicroRNAs in IgA nephropathy.Renal failure · 2021Review
- Identification of miRNA-mRNA network and immune-related gene signatures in IgA nephropathy by integrated bioinformatics analysis.BMC nephrology · 2021Article
- Immune regulation in renal inflammation.Cell and tissue research · 2021Review
- The Non-Coding RNA Landscape in IgA Nephropathy-Where Are We in 2021?Journal of clinical medicine · 2021Review
- Low serum IgG4 level: a potential diagnostic biomarker for IgA nephropathy.Annals of translational medicine · 2021Article
- Monozygotic Twins Discordant for Immunoglobulin A Nephropathy Display Differences in DNA Methylation and Gene Expression.Kidney diseases (Basel, Switzerland) · 2021Article
- B cell and monocyte phenotyping: A quick asset to investigate the immune status in patients with IgA nephropathy.PloS one · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicroRNA-155 (miR-155) is an important immune regulator of T lymphocyte subgroup balance and function. This study was performed to explore the relationships between miR-155 expression in peripheral blood mononuclear cells (PBMCs), T lymphocyte subgroups, T lymphocyte regulators, and the clinical manifestations of IgA nephropathy (IgAN) patients.
methodsSixty biopsy-proven IgAN patients and 25 healthy controls were included in this study. The expression of miRNAs in PBMCs was determined using a microRNA microarray and real-time RT-PCR. T lymphocyte subgroups (Th1, Th2, Treg, and Th17), differentiation regulators (c-Maf, STATA-6, GATA-3, SOCS-1, and Fxop3), cytokines (IFN-γ, IL-5, IL-10, and IL-17), serum IgA1 glycosylation level, and Cosmc expression were examined using flow cytometry, qPCR, and ELISA.
resultsMicroarray analysis and qPCR suggested that the miR-155 level in PBMCs from IgAN patients was significantly lower than that in healthy controls (decreased 61%, 0.197 ± 0.068 vs 0.796 ± 0.13, p < 0.01). The expression of GATA-3 (0.08 ± 0.02 vs 0.04 ± 0.01, p = 0.035), SATA-6 (0.12 ± 0.02 vs 0.06 ± 0.01, p = 0.036), and SOCS-1 (0.04 ± 0.01 vs 0.03 ± 0.01, p = 0.01) was significantly higher in IgAN PBMCs compared to healthy controls, while that of Foxp3 (0.013 ± 0.003 vs 0.040 ± 0.01, p = 0.026) and Cosmc (0.08 ± 0.02 vs 0.19 ± 0.04, p = 0.024) was remarkably lower. Flow cytometric analysis revealed that the percentages of peripheral blood Th1 (17.35 ± 1.22 vs 20.89 ± 1.22, p = 0.042) and Treg cells (1.86 ± 0.15 vs 2.48 vs 0.26, p = 0.031) were significantly lower in IgAN patients than in normal controls; however, the percentages of Th2 (1.73 ± 0.29 vs 1.04 ± 0.18, p = 0.046) and Th17 (4.09 ± 0.45 vs 2.06 ± 0.21, p < 0.001) were remarkably higher. ELISA results indicated that serum Th1 cytokine INF-γ (40.77 ± 8.39 vs 83.02 ± 17.4 pg/mL, p = 0.035) and Treg cytokine IL-10 (0.77 ± 0.28 vs 4.18 ± 1.34 pg/mL, p = 0.02) levels were lower, while Th2 cytokine IL-5 (1.02 ± 0.17 vs 0.65 ± 0.07 pg/mL, p = 0.04) and Th17 cytokine IL-17 (53.78 ± 12.20 vs 28.87 ± 4.59 pg/mL, p = 0.05) were significantly higher in IgAN patients than in normal controls. Significant correlations were found between miR-155 levels and Foxp3, Cosmc level, 24-h urine protein amount, urine RBC count, serum IgA concentration, and IgA1 dys-glycosylation level.
conclusionA remarkably lower expression of peripheral lymphocyte miR-155 was observed in IgAN patients, leading to T lymphocyte subgroup drifting (increases in Th2 and Th17 along with decreases in Th1 and Treg), which inhibits Cosmc gene expression and worsens the aberrant glycosylation of IgA1 in IgAN patients. These results suggest that miR-155 may play an important role in the pathogenesis of IgAN and could serve as a potential disease biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.